The ongoing dispute between UniQure and the FDA raises critical questions regarding regulatory practices in gene therapy, particularly for Huntington's disease treatments.
The implications of this case extend beyond UniQure, potentially affecting how future therapies are evaluated and approved, especially in the context of rare diseases.
As the landscape of gene therapy evolves, stakeholders must consider the operational and infrastructural adjustments necessary to navigate these regulatory challenges.